Compounds like ZMC1 that stabilize mutant protein to enhance p53-mediated tumor cell apoptosis and decrease growth (Blanden et al., 2020; Blanden et al., 2015; Yu et al., 2012) selectively increased ERMS apoptosis in tp53-/- + TP53C176F but not in tp53-/- tumors, further highlighting our assay as an effective in vivo drug efficacy screening tool. Here, TP53 is linked to neoplasm.